Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities

Area of Science:

• Oncology
• Environmental Medicine
• Pathology

Background:

• Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis, posing a growing global health challenge.
• Its rarity, late diagnosis, and limited therapeutic options necessitate a deeper understanding of its development and management.
• Environmental factors and underlying genetic predispositions are key contributors to PM pathogenesis.

Purpose of the Study:

• To enhance medical professionals' understanding of PM risk factors and environmental influences.
• To provide a comprehensive overview of diagnostic modalities, including novel immunohistochemical markers.
• To highlight recent advancements in prognostic scoring and treatment strategies for PM.

Main Methods:

• Review of current literature on pleural mesothelioma epidemiology, pathogenesis, diagnosis, and treatment.
• Emphasis on immunohistochemical markers (BAP1, MTAP) and genetic testing (FISH p16/CDKN2A deletion).
• Analysis of recent clinical trial data and prognostic scoring systems.

Main Results:

• BAP1 and MTAP immunohistochemistry are significant diagnostic tools, with MTAP as a surrogate for FISH p16/CDKN2A deletion.
• The tumor inflammatory microenvironment is crucial for developing personalized treatments.
• Recent advancements offer improved prognostic assessment and therapeutic avenues.

Conclusions:

• A comprehensive understanding of PM's complexity, from environmental triggers to molecular mechanisms, is vital.
• Early diagnosis and personalized treatment strategies targeting BAP1, MTAP, and the tumor microenvironment are critical for improving patient outcomes.
• Continued research into prevention, mutation analysis, diagnosis, and treatment is essential for combating this disease.